Click here to bypass content and jump to navigation

 

BEPREVE

Physician Resources

Additional Information

Patient Rebate
Click here to access the BEPREVE rebate offer.

BEPREVE Dosing Information:

dosing sheet Click here to download the BEPREVE Dosing Instructions sheet in English.
dosing-spanish Haga clic aquí para descargar la hoja de instrucciones de dosificación BEPREVE en Español [Spanish].

Bibliography
  • Abelson MB, Spitalny L. Combined analysis of two studies using the conjunctival allergen challenge model to evaluate olopatadine hydrochloride, a new ophthalmic antiallergic agent with dual activity. Am J Ophthalmol. 1998;125(6):797-804.
  • Clark JC, Williams JI, Gow JA, Abelson MB, McNamara TR, for the Bepotastine Besilate Ophthalmic Solutions Clinical Study Group. Poster presented at: 24th Annual EAC. Palm Beach, FL; May 6-9, 2010.
  • Williams JI, Schooley GL, Gow JA, McNamara TR. Bepreve™ 1.5% provides clinically meaningful reduction in allergen-induced ocular itching for subjects in an analysis of two phase 3 conjunctival allergen challenge (CAC) clinical trials [AAAAI abstract 151]. J Allergy Clin Immunol. 2010;125(2)(suppl 1):AB38.

IMPORTANT SAFETY INFORMATION: BEPREVE is for topical ophthalmic use only. To minimize risk of contamination, do not touch the dropper tip to any surface. Keep the bottle closed when not in use. BEPREVE should not be used to treat contact lens–related irritation. Remove contact lenses prior to instillation of BEPREVE. The most common adverse reaction occurring in approximately 25% of patients was a mild taste following instillation. Other adverse reactions occurring in 2%-5% of patients were eye irritation, headache, and nasopharyngitis.

Back to Top